Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in New Jersey, announced that CAMBIA(TM) (diclofenac potassium for oral solution) is now available in the United States for the acute treatment of migraine with or without aura. CAMBIA was approved by the U.S. Food and Drug Administration in June 2009.

Leggi l’articolo intero.


Leave a Reply

You must be logged in to post a comment.